Winning HRTX Stock Forecast: Heron Therapeutics Gained 46.99% 3 Months After Strong Bullish Signal

“HTX-011 is the only long-acting local anesthetic to demonstrate significantly reduced postoperative pain and opioid use through 72 hours compared to bupivacaine solution, the standard-of-care local anesthetic for postoperative pain management, in Phase 3 studies. We look forward to working towards the submission of an NDA to the FDA for HTX-011 in the second half of 2018.”

– Barry D. Quart, Pharm.D., CEO of Heron Therapeutics.


Just in three months from March 25th, 2018, Heron Therapeutics Inc (NYSE: HRTX) has gained 46.99%. The main reason for

Read More

Quick Win By The Algorithm: Immunomedics Gained 15.21% For 3 Days

Quick Win By The Algorithm

On Aug. 22, 2017 immunomedics analysis

Read The Full Forecast

Stock Market Outlook Quick Win by the Algorithm: FDA Approval Expedites OMER’s Growth

Quick Win by the Algorithm

Read The Full Forecast

quick win